NIH Highlighted Topic: Computational Modeling of Complex Processes Across Biological Scales
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is encouraging innovative research proposals focused on computational modeling of complex biological processes across multiple spatial and temporal scales. This highlighted topic supports multidisciplinary projects developing advanced multiscale computational models that integrate molecular, cellular, tissue, organ, organismal, behavioral, and population-level processes to improve understanding of human health and disease.
NIH is particularly interested in projects that improve the rigor, reproducibility, transparency, interoperability, and reusability of computational multiscale models while fostering collaborative modeling communities across biomedical disciplines. Companies developing AI-enabled modeling platforms, systems biology software, digital twin technologies, computational biology tools, biomedical simulation systems, cloud-based modeling infrastructure, or advanced predictive analytics platforms may be strong candidates for funding.
Areas of interest include infectious disease modeling, cancer systems biology, cardiovascular and pulmonary modeling, neuroscience simulation, aging and Alzheimer’s disease research, autoimmune disease modeling, substance use disorder modeling, precision medicine, microbiome dynamics, organ-system interactions, and Novel Alternative Methods (NAMs) for therapeutic development and safety assessment. NIH is also encouraging projects integrating AI, machine learning, FAIR data practices, uncertainty quantification, cloud-native infrastructure, and interoperable data science workflows.
Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.
This highlighted topic is supported by numerous NIH Institutes and Offices including NIAID, NCI, NHLBI, NIA, NIMH, NIDA, NIBIB, NLM, NIDCR, NCCIH, ORWH, and ODSS, all of which are seeking transformative innovations that improve computational modeling, biomedical simulation, translational research, and precision health outcomes.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of computational biology platforms, AI-enabled simulation systems, multiscale modeling infrastructure, and biomedical data science technologies.
Eligible activities may include:
AI and machine learning platforms for multiscale biological modeling
Computational biology and systems biology software development
Digital twin and predictive simulation technologies
Biomedical modeling infrastructure and cloud-native computational platforms
FAIR data integration, interoperability, and reproducibility systems
Cancer, infectious disease, cardiovascular, neurological, and autoimmune disease modeling tools
Precision medicine and personalized health prediction platforms
Organ-system and brain-body interaction simulation technologies
Aging, Alzheimer’s disease, and lifespan modeling systems
Novel Alternative Methods (NAMs) for therapeutic testing and safety evaluation
Biomarker discovery and predictive analytics platforms
Computational neuroscience and neural circuit simulation systems
Microbiome, immunology, and host-environment interaction models
Population health, epidemiological, and behavioral systems modeling
Biomedical imaging integration and quantitative uncertainty analysis tools
Open-source computational workflow and model-sharing infrastructure
Prototype development, translational studies, and validation research
Commercialization planning, regulatory preparation, and scale-up activities
Funding may also support personnel, software engineering, cloud computing infrastructure, AI model development, computational simulation research, data harmonization, bioinformatics analysis, systems biology validation studies, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable computational biology or healthcare technology solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
